These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 16290163)

  • 1. Synthesis and biological activity of novel 4,4-difluorobenzazepine derivatives as non-peptide antagonists of the arginine vasopressin V1A receptor.
    Shimada Y; Taniguchi N; Matsuhisa A; Akane H; Kawano N; Suzuki T; Tobe T; Kakefuda A; Yatsu T; Tahara A; Tomura Y; Kusayama T; Wada K; Tsukada J; Orita M; Tsunoda T; Tanaka A
    Bioorg Med Chem; 2006 Mar; 14(6):1827-37. PubMed ID: 16290163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic properties of YM218, a novel, potent, nonpeptide vasopressin V1A receptor-selective antagonist.
    Tsukada J; Tahara A; Tomura Y; Kusayama T; Wada K; Ishii N; Taniguchi N; Suzuki T; Yatsu T; Uchida W; Shibasaki M
    Vascul Pharmacol; 2005 Jan; 42(2):47-55. PubMed ID: 15722249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin.
    Manning M; Cheng LL; Stoev S; Bankowski K; Przybyiski J; Klis WA; Sawyer WH; Wo NC; Chan WY
    J Pept Sci; 1995; 1(1):66-79. PubMed ID: 9222985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and structure-activity relationships of amide derivatives of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetic acid as selective arginine vasopressin V2 receptor agonists.
    Tsukamoto I; Koshio H; Kuramochi T; Saitoh C; Yanai-Inamura H; Kitada-Nozawa C; Yamamoto E; Yatsu T; Shimada Y; Sakamoto S; Tsukamoto S
    Bioorg Med Chem; 2009 Apr; 17(8):3130-41. PubMed ID: 19321349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orally active, nonpeptide vasopressin V2 receptor antagonists: a novel series of 1-[4-(benzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepines and related compounds.
    Ogawa H; Yamashita H; Kondo K; Yamamura Y; Miyamoto H; Kan K; Kitano K; Tanaka M; Nakaya K; Nakamura S; Mori T; Tominaga M; Yabuuchi Y
    J Med Chem; 1996 Aug; 39(18):3547-55. PubMed ID: 8784453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and evaluation of spirobenzazepines as potent vasopressin receptor antagonists.
    Xiang MA; Chen RH; Demarest KT; Gunnet J; Look R; Hageman W; Murray WV; Combs DW; Patel M
    Bioorg Med Chem Lett; 2004 Jun; 14(11):2987-9. PubMed ID: 15125974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo.
    Tahara A; Tomura Y; Wada KI; Kusayama T; Tsukada J; Takanashi M; Yatsu T; Uchida W; Tanaka A
    J Pharmacol Exp Ther; 1997 Jul; 282(1):301-8. PubMed ID: 9223568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetamide derivatives as novel arginine vasopressin V(2) receptor agonists.
    Tsukamoto I; Koshio H; Akamatsu S; Kuramochi T; Saitoh C; Yatsu T; Yanai-Inamura H; Kitada C; Yamamoto E; Sakamoto S; Tsukamoto S
    Bioorg Med Chem; 2008 Nov; 16(21):9524-35. PubMed ID: 18835174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
    Yamamura Y; Nakamura S; Itoh S; Hirano T; Onogawa T; Yamashita T; Yamada Y; Tsujimae K; Aoyama M; Kotosai K; Ogawa H; Yamashita H; Kondo K; Tominaga M; Tsujimoto G; Mori T
    J Pharmacol Exp Ther; 1998 Dec; 287(3):860-7. PubMed ID: 9864265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping the binding site of six nonpeptide antagonists to the human V2-renal vasopressin receptor.
    Macion-Dazard R; Callahan N; Xu Z; Wu N; Thibonnier M; Shoham M
    J Pharmacol Exp Ther; 2006 Feb; 316(2):564-71. PubMed ID: 16234409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on human vasopressin and oxytocin receptors.
    Tahara A; Tsukada J; Tomura Y; Kusayama T; Wada K; Ishii N; Taniguchi N; Suzuki T; Yatsu T; Uchida W; Shibasaki M
    Pharmacol Res; 2005 Mar; 51(3):275-81. PubMed ID: 15661579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
    Manning M; Stoev S; Chini B; Durroux T; Mouillac B; Guillon G
    Prog Brain Res; 2008; 170():473-512. PubMed ID: 18655903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasopressin stimulates insulin release from islet cells through V1b receptors: a combined pharmacological/knockout approach.
    Oshikawa S; Tanoue A; Koshimizu TA; Kitagawa Y; Tsujimoto G
    Mol Pharmacol; 2004 Mar; 65(3):623-9. PubMed ID: 14978240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 2-phenyl-4'-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]benzanil ide derivatives.
    Matsuhisa A; Tanaka A; Kikuchi K; Shimada Y; Yatsu T; Yanagisawa I
    Chem Pharm Bull (Tokyo); 1997 Nov; 45(11):1870-4. PubMed ID: 9396163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next-generation spirobenzazepines: identification of RWJ-676070 as a balanced vasopressin V1a/V2 receptor antagonist for human clinical studies.
    Xiang MA; Rybczynski PJ; Patel M; Chen RH; McComsey DF; Zhang HC; Gunnet JW; Look R; Wang Y; Minor LK; Zhong HM; Villani FJ; Demarest KT; Damiano BP; Maryanoff BE
    Bioorg Med Chem Lett; 2007 Dec; 17(23):6623-8. PubMed ID: 17942308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.
    Serradeil-Le Gal C; Lacour C; Valette G; Garcia G; Foulon L; Galindo G; Bankir L; Pouzet B; Guillon G; Barberis C; Chicot D; Jard S; Vilain P; Garcia C; Marty E; Raufaste D; Brossard G; Nisato D; Maffrand JP; Le Fur G
    J Clin Invest; 1996 Dec; 98(12):2729-38. PubMed ID: 8981918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 4'-[5-(substituted methylidene)-2,3,4,5-tetrahydro-1H-1-ben zoazepine-1-carbonyl]benzanilide and 4'-[5-(substituted methyl)-2,3-dihydro-1H-1-benzoazepine-1- carbonyl]benzanilide derivatives.
    Matsuhisa A; Kikuchi K; Sakamoto K; Yatsu T; Tanaka A
    Chem Pharm Bull (Tokyo); 1999 Mar; 47(3):329-39. PubMed ID: 10212383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation of highly potent and selective non-peptide antagonists of the arginine vasopressin V1A receptor by introduction of a 2-ethyl-1H-1-imidazolyl group.
    Shimada Y; Akane H; Taniguchi N; Matsuhisa A; Kawano N; Kikuchi K; Yatsu T; Tahara A; Tomura Y; Kusayama T; Wada K; Tsukada J; Tsunoda T; Tanaka A
    Chem Pharm Bull (Tokyo); 2005 Jul; 53(7):764-9. PubMed ID: 15997131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected].
    Ali F; Raufi MA; Washington B; Ghali JK
    Cardiovasc Drug Rev; 2007; 25(3):261-79. PubMed ID: 17919259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 4-(1,4,5,6-tetrahydroimidazo[4,5-d][1]benzoazepine-6-carbonyl)benzanili de derivatives and 4'-(5,6-dihydro-4H-thiazolo[5,4-d][1]benzoazepine-6-carbonyl)benzanilid e derivatives.
    Matsuhisa A; Taniguchi N; Koshio H; Yatsu T; Tanaka A
    Chem Pharm Bull (Tokyo); 2000 Jan; 48(1):21-31. PubMed ID: 10705470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.